Skip to content
DataLookout
Menu

IRONDOSENCT06427343

The Effects of Low-Dose Versus High-Dose Intravenous IRON Therapy With Ferric DerisomaltOSE in Patients With Chronic Heart Failure and Iron Deficiency

StatusRecruiting
PhasePhase 4
Primary completion (estimated)

At risk: Primary completion moved at least 10 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates pushed to Aug 1, 2027 Show 4 more changesShow less
    • Eligibility criteria shortened, about 6 words
    • Primary endpoints: details revised at 1 of 1 entry
    • Secondary endpoints: details revised at 5 of 13 entries
    • Study description revised
  2. Notable Primary endpoint revisedv2 Show 4 more changesShow less
    • Eligibility criteria shortened, about 2 words
    • Secondary endpoints revised (13)
    • Study description revised
    • Site contact updated
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in peak VO2 (ml/min/kg)
Timeframe: Baseline to Week 52

Secondary (13)

Change in VO2 at ventilatory threshold (ml/min)
Change in heart rate at peak exercise (bpm)
Change in peak respiratory exchange ratio
Change in 6-minute walking distance (m)
Change in myocardial iron content by cardiac magnetic resonance imaging T2 star
Show 8 moreShow less
Change in skeletal muscle iron content by magnetic resonance imaging T2 star
Change in the clinical summary score by Kansas City Cardiomyopathy Questionnaire (KCCQ)
Change in the EQ-5D-5L questionnaire indexed value
Change in cognitive function score by Mini-Mental State Examination (MMSE)
Change in concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP, pg/mL)
Change in left ventricular ejection fraction (LVEF, %)
Change in left ventricular global longitudinal stress (LVGLS, %)
Mortality and heart failure-related hospitalization rates

Arms and interventions

High doseExperimental

Participants randomized to this arm will receive repeat iron dosing as long as the serum ferritin was not \>700 ng/mL, or if TSAT was not \>40% during follow-up. Iron to be administered as ferric derisomaltose. Ferric derisomaltose will be administered according to the dosing schedule determined by the patient's body weight and hemoglobin value. Infused over a minimum of 15 mins for doses up to and including 1000mg, and a minimum of 30 mins for doses \>1000mg.

Low doseActive comparator

Participants randomized to this arm will receive repeat iron dosing if ferritin \<100 ng/mL or if ferritin 100-300 ng/mL and TSAT \<20% during follow-up. Iron to be administered as ferric derisomaltose in analogy to high-dose arm.

Drugs: High-dose ferric derisomaltose, Low-dose ferric derisomaltose

Sites

1 site in 1 country

  • China-Japan Friendship HospitalBeijing, Beijing Municipality, China